Thursday December 10, 2020 0 comments
CENTENNIAL -- AlloSource, one of the largest allograft providers in the U.S., announced the Journal of Orthopaedic Surgery and Research published the company's science in an article titled "Cryopreserved, Thin, Laser-Etched Osteochondral Allograft maintains the functional components of articular cartilage after 2 years of storage."
The article describes data supporting that ProChondrix Cryopreserved (CR) Osteochondral Allograft has several crucial elements that encourage cartilage healing including high chondrocyte viability, an intact extracellular matrix and the presence of native growth factors after two years of storage at −80°C.
ProChondrix CR's chondrocyte viability was shown be 94.97% ± 3.38% (after thawing) as compared to 98.83% ± 0.43% viability data obtained from fresh cartilage samples, the company said.
Chondrocyte viability is maintained because AlloSource cryopreserves cartilage tissue within 72 hours of tissue donation.
"Despite improvements in treatment options and techniques, articular cartilage repair continues to be a challenge for orthopaedic surgeons because of the limited availability of conventionally used refrigerated osteochondral allografts," said Dr. Ross Wilkins, AlloSource senior medical director.
"AlloSource's cryopreservation technology provides a readily available and scientifically sound allograft solution."
Founded in 1994, AlloSource is a nonprofit leader in providing allografts that maximize tissue donation to help surgeons heal their patients.